WO2014138426A3 - Methods and compositions for reducing body fat and adipocytes - Google Patents

Methods and compositions for reducing body fat and adipocytes Download PDF

Info

Publication number
WO2014138426A3
WO2014138426A3 PCT/US2014/021288 US2014021288W WO2014138426A3 WO 2014138426 A3 WO2014138426 A3 WO 2014138426A3 US 2014021288 W US2014021288 W US 2014021288W WO 2014138426 A3 WO2014138426 A3 WO 2014138426A3
Authority
WO
WIPO (PCT)
Prior art keywords
adipocytes
compositions
methods
body fat
reducing body
Prior art date
Application number
PCT/US2014/021288
Other languages
French (fr)
Other versions
WO2014138426A2 (en
Inventor
Murat V. Kalayoglu
Michael S. Singer
Original Assignee
Topokine Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Topokine Therapeutics, Inc. filed Critical Topokine Therapeutics, Inc.
Publication of WO2014138426A2 publication Critical patent/WO2014138426A2/en
Publication of WO2014138426A3 publication Critical patent/WO2014138426A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/489—Sophora, e.g. necklacepod or mamani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A61K36/074—Ganoderma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/22—Anacardiaceae (Sumac family), e.g. smoketree, sumac or poison oak
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A61K36/8994—Coix (Job's tears)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Abstract

Provided are methods and compositions for reducing body fat, and/or adipocytes in a subject, comprising administering a compound and/or natural product extract that is an activator of adenosine monophosphate-activated kinase (AMPK).
PCT/US2014/021288 2013-03-07 2014-03-06 Methods and compositions for reducing body fat and adipocytes WO2014138426A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361773942P 2013-03-07 2013-03-07
US61/773,942 2013-03-07

Publications (2)

Publication Number Publication Date
WO2014138426A2 WO2014138426A2 (en) 2014-09-12
WO2014138426A3 true WO2014138426A3 (en) 2014-10-30

Family

ID=51492097

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/021288 WO2014138426A2 (en) 2013-03-07 2014-03-06 Methods and compositions for reducing body fat and adipocytes

Country Status (1)

Country Link
WO (1) WO2014138426A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3009138T3 (en) * 2014-09-01 2019-08-05 Vidya Herbs Pvt Ltd MANGIFERA EXTRACT FOR MANAGING OBES AND / OR WEIGHT
EP3124047A1 (en) * 2015-07-28 2017-02-01 Merz Pharma GmbH & Co. KGaA Pentacyclic triterpenoids for injection lipolysis
AU2016314546C1 (en) * 2015-08-28 2021-07-22 Caliway Biopharmaceuticals Co., Ltd. Pharmaceutical composition used for reducing localised fat and use of pharmaceutical composition
US11318110B2 (en) 2015-08-28 2022-05-03 Caliway Biopharmaceuticals Co., Ltd. Pharmaceutical composition for reducing local fat and uses thereof
US10369179B2 (en) 2015-09-13 2019-08-06 Vidya Herbs, Inc. Composition of Mangifera indica
FR3042411B1 (en) * 2015-10-20 2019-07-12 Valbiotis COMPOSITION COMPRISING A MIXTURE OF PARTICULAR MOLECULES AND USE FOR ACTING ON GLUCIDIC AND / OR LIPID METABOLISM
CA3033041A1 (en) * 2016-08-26 2018-03-01 Caliway Biopharmaceuticals Co., Ltd. A subcutaneous injection formulation for reducing body weight and uses thereof
US11896600B2 (en) 2019-09-21 2024-02-13 Vidya Herbs, Inc. Composition and method of using eicosanoyl-5-hydroxytryptamide for treating neurodegenerative disorders
US11452703B2 (en) * 2020-05-21 2022-09-27 Peregrine Ophthalmic PTE LTD. Methods and compositions for reducing adipocyte numbers

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020136785A1 (en) * 2000-11-07 2002-09-26 Chun-Su Yuan Ginseng berry extracts and pharmaceutical compositions from ginseng berry for the treatment of type 2 diabetes and obesity
WO2003011267A1 (en) * 2001-07-31 2003-02-13 The Nisshin Oillio, Ltd. Antiobesity drugs and materials thereof
US20030212014A1 (en) * 2000-08-09 2003-11-13 Neil Ruderman Methods fo treating conditions associated with insulin resistance with aicar, (5-amino-4-imidazole carboxamide riboside) and related compounds
US20050171027A1 (en) * 2003-12-29 2005-08-04 President And Fellows Of Harvard College Compositions for treating or preventing obesity and insulin resistance disorders
US20050267221A1 (en) * 2004-05-14 2005-12-01 Research Development Foundation Use of curcumin and analogues thereof as inhibitors of ACC2
WO2007081808A2 (en) * 2006-01-05 2007-07-19 Deviris Inc. Compounds and derivatives for the treatment of medical conditions by modulating hormone-sensitive lipase activity
US20080004217A1 (en) * 1998-12-30 2008-01-03 Applied Research Systems Ars Treatment of hiv-associated dysmorphia/dysmetabolic syndrome (hadds) with or without lipodystrophy
US20100152275A1 (en) * 2008-12-11 2010-06-17 Kaloness, Inc. Drug or Supplement Combination with Conjugated Linoleic Acid for Fat Loss in Mammals
WO2011152692A2 (en) * 2010-06-03 2011-12-08 주식회사 리스토어랩스 Anti-obesity cream composition containing fucoxanthin
TW201231046A (en) * 2011-01-25 2012-08-01 Univ Nat Cheng Kung Pharmaceutical composition or Toona sinensis extract for decreasing weight or body fat

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080004217A1 (en) * 1998-12-30 2008-01-03 Applied Research Systems Ars Treatment of hiv-associated dysmorphia/dysmetabolic syndrome (hadds) with or without lipodystrophy
US20030212014A1 (en) * 2000-08-09 2003-11-13 Neil Ruderman Methods fo treating conditions associated with insulin resistance with aicar, (5-amino-4-imidazole carboxamide riboside) and related compounds
US20020136785A1 (en) * 2000-11-07 2002-09-26 Chun-Su Yuan Ginseng berry extracts and pharmaceutical compositions from ginseng berry for the treatment of type 2 diabetes and obesity
WO2003011267A1 (en) * 2001-07-31 2003-02-13 The Nisshin Oillio, Ltd. Antiobesity drugs and materials thereof
US20050171027A1 (en) * 2003-12-29 2005-08-04 President And Fellows Of Harvard College Compositions for treating or preventing obesity and insulin resistance disorders
US20050267221A1 (en) * 2004-05-14 2005-12-01 Research Development Foundation Use of curcumin and analogues thereof as inhibitors of ACC2
WO2007081808A2 (en) * 2006-01-05 2007-07-19 Deviris Inc. Compounds and derivatives for the treatment of medical conditions by modulating hormone-sensitive lipase activity
US20100152275A1 (en) * 2008-12-11 2010-06-17 Kaloness, Inc. Drug or Supplement Combination with Conjugated Linoleic Acid for Fat Loss in Mammals
WO2011152692A2 (en) * 2010-06-03 2011-12-08 주식회사 리스토어랩스 Anti-obesity cream composition containing fucoxanthin
TW201231046A (en) * 2011-01-25 2012-08-01 Univ Nat Cheng Kung Pharmaceutical composition or Toona sinensis extract for decreasing weight or body fat

Non-Patent Citations (20)

* Cited by examiner, † Cited by third party
Title
CARLOS ROBERTO PORTO DECHANDT ET AL.: "Combretum lanceolatum flowers extract shows antidiabetic activity through activation of AMPK by quercetin.", BRAZILIAN JOURNAL OF PHARMACOGNOSY., vol. 23, no. 2, 2013, pages 291 - 300, XP018506527 *
CHEN YY. ET AL.: "Methyl cinnamate inhibits adipocyte differentiation via activation of the CaMKK2-AMPK pathway in 3T3-Ll preadipocytes", J AGRIC CHEM, vol. 60, no. 4, 2012, pages 955 - 963 *
CHI Y ET AL.: "Nonsteroidal anti-inflammatory drug flufenamic acid is a potent activator of AMP-activated protein kinase''.", J PHARMACOL EXP THER., vol. 339, no. 1, October 2011 (2011-10-01), pages 257 - 266 *
HA DO T ET AL.: "Adlay seed extract (Coix lachryma-jobi L.) decreased adipocyte differentiation and increased glucose uptake in 3T3-L1 cells''.", J MED FOOD., vol. 13, no. 6, December 2010 (2010-12-01), pages 1331 - 1339 *
HA DO T ET AL.: "The selected flavonol glycoside derived from Sophorae Flos improves glucose uptake and inhibits adipocyte differentiation via activation AMPK in 3T3-L1 cells''.", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 20, no. 20, 2010, pages 6076 - 6081, XP027291116 *
HUANG B. ET AL.: "Cinnamaldehyde prevents adipocyte differentiation and adipogenesis via regulation of peroxisome proliferator-activated receptor-y (PPARy) and AMP - activated protein kinase (AMPK) pathways''.", J AGRIC FOOD CHEM, vol. 59, no. 8, 2011, pages 3666 - 3673 *
JUNG KH ET AL.: "Ganoderma lucidum extract stimulates glucose uptake in L6 rat skeletal muscle cells''.", ACTA BIOCHIM POL., vol. 53, no. 3, 2006, pages 597 - 601 *
KIM DY ET AL.: "Boesenbergia pandurata attenuates diet-induced obesity by activating AMP-activated protein kinase and regulating lipid metabolism''.", INT J MOL SCI., vol. 13, no. 1, 2012, pages 994 - 1005 *
LEE NY ET AL.: "Inhibitory Effect of Vitamin U (S-Methylmethionine Sulfonium Chloride) on Differentiation in 3T3-L1 Pre-adipocyte Cell Lines", ANN DERMATOL., vol. 24, no. 1, 2012, pages 39 - 44 *
MCCARTY MF.: "Hepatothermic therapy of obesity: rationale and an inventory of resources''.", MED HYPOTHESES., vol. 57, no. 3, 2001, pages 324 - 336, XP009030758, DOI: doi:10.1054/mehy.2000.1322 *
NINOMIYA K ET AL.: "Potent anti-obese principle from Rosa canina: structural requirements and mode of action of trans-tiliroside''.", BIOORG MED CHEM LETT., vol. 17, no. 11, 2007, pages 3059 - 3064, XP022068393, DOI: doi:10.1016/j.bmcl.2007.03.051 *
ONG KW ET AL.: "Chlorogenic acid stimulates glucose transport in skeletal muscle via AMPK activation: a contributor to the beneficial effects of coffee on diabetes. art e32718", PLOS ONE., vol. 7, no. 3, 2012, pages 1 - 11 *
ONO M ET AL.: "Antiadipogenic effect of dietary apigenin through activation of AMPK in 3T3-L1 cells''.", J AGRIC FOOD CHEM., vol. 59, no. 24, 28 December 2011 (2011-12-28), pages 13346 - 13352 *
PU P ET AL.: "Naringin ameliorates metabolic syndrome by activating AMP-activated protein kinase in mice fed a high-fat diet''.", ARCH BIOCHEM BIOPHYS., vol. 518, no. 1, 1 February 2012 (2012-02-01), pages 61 - 70 *
SEO JB ET AL.: "Foenumoside B from Lysimachia foenum-graecum inhibits adipocyte differentiation and obesity induced by high-fat diet", BIOCHEM BIOPHYS RES COMMUN., vol. 417, no. 2, 13 January 2012 (2012-01-13), pages 800 - 806 *
SHAH SS ET AL.: "Effect of piperine in the regulation of obesity-induced dyslipidemia in high-fat diet rats''.", INDIAN J PHARMACOL., vol. 43, no. 3, 2011, pages 296 - 299, XP009180479, DOI: doi:10.4103/0253-7613.81516 *
TAESUN PARK ET AL.: "Phytochemicals as Potential Agents for Prevention and Treatment of Obesity and Metabolic Diseases.", ANTI-OBESITY DRUG DISCOVERY AND DEVELOPMENT, vol. 1, 2011, pages 1 - 48 *
YU LI ET AL.: "AMPK Phosphorylates and Inhibits SREBP Activity to Attenuate Hepatic Steatosis and Atherosclerosis in Diet-induced Insulin Resistant Mice.", CELL METAB., vol. 13, no. 4, 6 April 2011 (2011-04-06), pages 376 - 388, XP028208831, DOI: doi:10.1016/j.cmet.2011.03.009 *
ZHANG F ET AL.: "Combretastatin A-4 activates AMP-activated protein kinase and improves glucose metabolism in db/db mice''.", PHARMACOL RES., vol. 57, no. 4, April 2008 (2008-04-01), pages 318 - 323, XP022637167, DOI: doi:10.1016/j.phrs.2008.03.002 *
ZHANG Y ET AL.: "Identification of benzophenone C-glucosides from mango tree leaves and their inhibitory effect on triglyceride accumulation in 3T3-L1 adipocytes''.", J AGRIC FOOD CHEM., vol. 59, no. 21, 9 November 2011 (2011-11-09), pages 11526 - 11533 *

Also Published As

Publication number Publication date
WO2014138426A2 (en) 2014-09-12

Similar Documents

Publication Publication Date Title
WO2014138426A3 (en) Methods and compositions for reducing body fat and adipocytes
IL263175B (en) Microbiota restoration therapy (mrt), compositions and methods of manufacture
MX2019001125A (en) Macrocycle kinase inhibitors.
HK1246800A1 (en) Oligosaccharide compositions for use in nutritional compositions, and methods of producing thereof
EP3352774A4 (en) Flavonoid compositions and methods of use
EP2964230A4 (en) Mixed lineage kinase inhibitors and method of treatments
MY181602A (en) Isochromene derivatives as phosphoinositide 3-kinases inhibitors
EP3013348A4 (en) A medicinal composition of amaranth extract origin having enriched nitrate content and a method of preparing the same
HK1216866A1 (en) Cosmetic, pharmaceutical or food composition including an extract of arthrobacter agilis rich in carotenoids
MX2018002546A (en) Compositions comprising an urolithin compound.
MX2015012205A (en) High fat human milk products.
HK1224237A1 (en) Use of an oily composition containing an extract of daylily in order to improve the firmness of the skin
PH12015502242B1 (en) Lutein composition suitable for infant food formulations
MX2015006370A (en) Herbal supplements and methods of use thereof.
IN2014DE02625A (en)
MY181719A (en) Fragrance and flavor compositions comprising neopentyl glycol diacetate
CA3056612A1 (en) Analogs of deutetrabenazine, their preparation and use
MX2015016603A (en) Corticosteroid compositions.
EP3080246A4 (en) Compositions and methods for producing and administering brown adipocytes
EP3528892A4 (en) Antioxidant-enriched multivitamin composition and methods of use
PH12017501979A1 (en) Pharmaceutical compound
MY193591A (en) Standardised extract of labisia pumila for weight reduction and nano-formulation thereof
MA40369A (en) Use of cistanche tubulosa extract in the preparation of drugs or foods for protecting ocular cells
ZA201804198B (en) Composition of olivetol and method of use reduce or inhibit the effects of tetrahydrocannabinol in the human body
GB2528406A (en) Prebiotic composition and method of its use

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14759616

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 14759616

Country of ref document: EP

Kind code of ref document: A2